These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31178281)

  • 21. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Panozzo J; Oh DY; Margo K; Morton DA; Piedrafita D; Mosse J; Hurt AC
    Antiviral Res; 2015 Aug; 120():66-71. PubMed ID: 26022199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
    Nakano T; Ishiwada N; Sumitani T; Uemori M; Isobe K;
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.
    Koyama K; Ogura Y; Nakai D; Watanabe M; Munemasa T; Oofune Y; Kubota K; Shinagawa A; Izumi T
    Drug Metab Dispos; 2014 Jun; 42(6):1031-8. PubMed ID: 24682756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S; Yoshida S; Yamaguchi H; Niwa S; Mitsui N; Tanigawa M; Shiosakai K; Yamanouchi N; Shiozawa T; Yamaguchi F
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
    Koyama K; Nakai D; Takahashi M; Nakai N; Kobayashi N; Imai T; Izumi T
    Drug Metab Dispos; 2013 Jan; 41(1):180-7. PubMed ID: 23091189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
    Kubo S; Kakuta M; Yamashita M
    Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
    Kubo S; Tokumitsu A; Tomozawa T; Kakuta M; Yamashita M
    J Infect Chemother; 2012 Feb; 18(1):69-74. PubMed ID: 21881920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
    Yamashita M
    Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
    Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Oba K; Togashi T; Morita K; Inagawa A; Okamura A; Yamazaki S; Shida S; Konno M; Kawamura N; Ishizaka A; Takada K; Tsubakihara K; Nagano N; Shibata M; Furuyama H; Matsuzono Y; Koike A; Murashita M; Hatae Y; Arioka H; Yamanaka T; Watanabe T; Tabata Y; Kumita Y; Hazama K; Akutsu Y; Aoyagi H; Tobise C; Azuma K; Yasoshima K; Sawada Y; Uetsuji K; Tsuchida A; Tsuchiyama A; Yasuda K; Odagawa Y; Yoshioka M
    J Infect Chemother; 2018 Jun; 24(6):449-457. PubMed ID: 29487035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Nov; 21(11):802-7. PubMed ID: 26410550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
    McKimm-Breschkin JL; Barrett S
    Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy outcomes of women exposed to laninamivir during pregnancy.
    Minakami H; Kubo T; Nakai A; Saito S; Unno N
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1084-7. PubMed ID: 25074683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate.
    Kawaguchi T; Arinaga-Hino T; Shimizu M; Tanikawa K; Tokushige T; Hirai S; Nagamatsu H; Tateishi H; Takata A; Ide T; Torimura T
    Intern Med; 2019 Sep; 58(17):2501-2505. PubMed ID: 31118398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Implications of Antiviral Resistance in Influenza.
    Li TC; Chan MC; Lee N
    Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
    Takemoto Y; Asai T; Ikezoe I; Yano T; Ichikawa M; Miyagawa S; Matsumoto J
    Chemotherapy; 2013; 59(5):373-8. PubMed ID: 24821568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms].
    Huang L; Zhou JF; Wei H; Shu YL
    Bing Du Xue Bao; 2012 Sep; 28(5):572-6. PubMed ID: 23233936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
    Hirotsu N; Saisho Y; Hasegawa T; Shishido T
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):173-182. PubMed ID: 29284320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.